Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Recruiting

Phase 2

Radiation with AguixStereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT04899908

Conditions

Brain Cancer

Brain Metastases

Melanoma

Lung Cancer

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Stereotactic Radiation

AGuIX gadolinium-based nanoparticles

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2024-10-24.